Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Reply. Silverberg JI, Guttman-Yassky E, Gontijo Lima R. N Engl J Med 2023;388:2299-2300.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Silverberg JI, Guttman-Yassky E, Gontijo Lima R. Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Reply. N Engl J Med 2023;388:2299-2300.
PMID: 37314719